

CURE SICKLE CELL.



National Heart, Lung,
and Blood Institute

PUBLICATIONS LIST

The Cure Sickle Cell Initiative is a collaborative, patient-focused research effort dedicated to accelerating the development of treatments aimed at genetic-based cures. Funded by the National Heart, Lung, and Blood Institute (NHLBI), the Initiative complements NHLBI's investment in sickle cell disease research by helping to fill gaps that cannot be covered by traditional funding methods. We bring together the sickle cell disease (SCD) community—patients, advocates, caregivers, providers, researchers, industry, etc.—and consider non traditional ways to advance research. The following is a list of publications produced since the Initiative started in 2018.

Table of Contents

Cell Collection and Conditioning	2
Cost Analysis	2
Data Resources	4
Gene Editing and Gene Therapy	4
Hematopoietic Cell Transplant (HCT)	5
Mental Health	6
Microfluidics	6
Post-Gene Therapy, Safety	8
Reproductive Health	9
SCD Community, Outreach	9
SCD Pathophysiology	9

CELL COLLECTION AND CONDITIONING

Challenges and Limitations of Mobilization and Stem Cell Collection for Gene Therapy of Sickle Cell Disease

15 December 2025

Tanhehco, Y. C., Thibodeaux, S., Shi, P. A., et al. (2025). Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease. *Blood Adv*, 9(24), 6524-6533. <https://doi.org/10.1182/bloodadvances.2025016054>

5-Azacytidine Depletes HSCs and Synergizes with an Anti-CD117 Antibody to Augment Donor Engraftment in Immunocompetent Mice

12 October 2021

Bankova, A. K., Pang, W. W., Velasco, B. J., et al. (2021). 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. *Blood Adv*, 5(19), 3900-3912. <https://doi.org/10.1182/bloodadvances.2020003841>

Parameters Affecting Successful Stem Cell Collections for Genetic Therapies in Sickle Cell Disease

10 January 2021

Justus, D. G. and Manis, J. P. (2021). Parameters affecting successful stem cell collections for genetic therapies in sickle cell disease. *Transfus Apher Sci*, 60(1), 103059. <https://doi.org/10.1016/j.transci.2021.103059>

COST ANALYSIS

Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms

10 November 2024

Basu, A. (2024). Financial impacts of paying for gene therapy for sickle cell disease under alternative pricing and financing mechanisms. *Value Health*, 28(2), 233-240. <https://doi.org/10.1016/j.jval.2024.10.3848>

Decreasing Alloimmunization-Specific Mortality in Sickle Cell Disease in the United States: Cost-Effectiveness of a Shared Transfusion Resource

26 January 2024

Ito, S., Pandya, A., Hauser, R. G., et al. (2024). Decreasing alloimmunization-specific mortality in sickle cell disease in the United States: cost-effectiveness of a shared transfusion resource. *Am J Hematol*, 99(4), 570-576. <https://doi.org/10.1002/ajh.27211>

Gene Therapy versus Common Care for Eligible Individuals with Sickle Cell Disease in the United States: A Cost-Effectiveness Analysis

23 January 2024

Basu, A., Winn, A. N., Johnson, K. M., et al. (2024). Gene therapy versus common care for eligible individuals with sickle cell disease in the United States: a cost-effectiveness analysis. *Ann Intern Med*, 177(2), 155-164. <https://doi.org/10.7326/M23-1520>

Associating Health-Related Quality-of-Life Score with Time Uses to Inform Productivity Measures in Cost-Effectiveness Analysis

06 March 2023

Jiao, B., and Basu, A. (2023). Associating health-related quality-of-life score with time uses to inform productivity measures in cost-effectiveness analysis. *Pharmacoeconomics*, 41(9), 1065-1077. <https://doi.org/10.1007/s40273-023-01246-x>

Long-Term Survival with Sickle Cell Disease: A Nationwide Cohort Study of Medicare and Medicaid Beneficiaries

03 July 2023

Jiao, B., Johnson, K. M., Ramsey, S. D., et al. (2023). Long-term survival with sickle cell disease: A nationwide cohort study of Medicare and Medicaid beneficiaries. *Blood Adv*. <https://doi.org/10.1182/bloodadvances.2022009202>

A Framework for a Health Economic Evaluation Model for Patients with Sickle Cell Disease to Estimate the Value of New Treatments in the United States of America

11 February 2023

Winn, A., Basu, A., and Ramsey, S. D. (2023). A framework for a health economic evaluation model for patients with sickle cell disease to estimate the value of new treatments in the United States of America. *Pharmacoecon Open*, 7(2), 313–320. <https://doi.org/10.1007/s41669-023-00390-6>

Lifetime Medical Costs Attributable to Sickle Cell Disease Among Nonelderly Individuals with Commercial Insurance

27 January 2023

Johnson, K., Jiao, B., Ramsey, S. D., et al. (2023). Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. *Blood Adv*, 7(3), 365–374. <https://doi.org/10.1182/bloodadvances.2021006281>

Prevalence of Comorbidities Associated with Sickle Cell Disease among Non-elderly Individuals with Commercial Insurance – A Retrospective Cohort Study

29 November 2022

Ramsey, S. D., Bender, M. A., Li, L., et al. (2022). Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance-A retrospective cohort study. *PLoS One*, 17(11), e0278137. <https://doi.org/10.1371/journal.pone.0278137>

Application of Validated Mapping Algorithms between Generic PedsQL Scores and Utility Values to Individuals with Sickle Cell Disease

17 June 2022

Jiao, B., Hankins, J. S., Devine, B., et al. (2022). Application of validated mapping algorithms between generic PedsQL scores and utility values to individuals with sickle cell disease. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation*, 31(9), 2729–2738. <https://doi.org/10.1007/s11136-022-03167-2>

Development of a Conceptual Model for Evaluating New Non-Curative and Curative Therapies for Sickle Cell Disease

28 April 2022

Johnson, K., Jiao, B., Bender, M., et al. (2022). Development of a conceptual model for evaluating new non-curative and curative therapies for sickle cell disease. *PLoS One*, 17(4), e0267448. <https://doi.org/10.1371/journal.pone.0267448>

Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis

26 April 2022

Baldwin, Z., Jiao, B., Basu, A., et al. (2022). Medical and non-medical costs of sickle cell disease and treatments from a US perspective: A systematic review and landscape analysis. *Pharmacoecon Open*, 6(4), 469–481. <https://doi.org/10.1007/s41669-022-00330-w>

A Landscape Analysis and Discussion of Value of Gene Therapies for Sickle Cell Disease

18 April 2022

Quach, D., Jiao, B., Basu, A., et al. (2022). A landscape analysis and discussion of value of gene therapies for sickle cell disease. *Expert Rev Pharmacoecon Outcomes Res*, 22(6), 891–911. <https://doi.org/10.1080/14737167.2022.2060823>

Health State Utilities for Sickle Cell Disease: A Catalog Prepared from a Systematic Review

February 2022

Jiao, B., Basu, A., Ramsey, S. D., et al. (2022). Health state utilities for sickle cell disease: A catalog prepared from a systematic review. *Value Health*. <https://doi.org/10.1016/j.jval.2021.08.002>

The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature

09 August 2021

Jiao, B., Basu, A., Roth, J. et al. The use of cost-effectiveness analysis in sickle cell disease: A critical review of the literature. *Pharmacoecon*, 39, 1225–1241 (2021). <https://doi.org/10.1007/s40273-021-01072-z>

Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease

01 April 2021

Krishnamurti, L. (2021). Gaps in Medicaid coverage and financial toxicity: a health disparity in hematopoietic cell transplantation for sickle cell disease. *Transplant and Cell Ther*, 27(4), 284-285. <https://doi.org/10.1016/j.jtct.2021.03.016>

DATA RESOURCES

CureSCi Metadata Catalog—Finding and Harmonizing Studies for Secondary Analysis of Hydroxyurea Discontinuation for Sickle Cell Disease

23 April 2025

Wu, X., Stratford, J., Kesler, K., et al. (2025). CureSCi Metadata Catalog— Finding and harmonizing studies for secondary analysis of hydroxyurea discontinuation in sickle cell disease. *PLoS One*, 20(4), e0309572. <https://doi.org/10.1101/2024.08.15.608203>

Creating an Automated Contemporaneous Cohort in Sickle Cell Anemia to Predict Survival After Disease-Modifying Therapy

26 July 2023

Cronin, R. M., Wuichet, K., Ghafari, D. L., et al. (2023). Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy. *Blood Adv*, 7(15), 3775-3782. <https://doi.org/10.1182/bloodadvances.2022008692>

CureSCi Metadata Catalog –Making Sickle Cell Studies Findable

12 December 2022

Pan, H., Ives, C., Mandal, M., et al. (2022). CureSCi Metadata Catalog-Making sickle cell studies findable. *PLoS One*, 17(12), e0256248. <https://doi.org/10.1371/journal.pone.0256248>

GENE EDITING AND GENE THERAPY

Gene Editing without Ex Vivo Culture Evades Genotoxicity in Human Hematopoietic Stem Cells

06 February 2025

Zeng, J., Nguyen, M. A., Liu, P., et al. (2025). Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells. *Cell Stem Cell*, 32(2), 191-208. <https://doi.org/10.1016/j.stem.2024.11.001>

Treatment with Curative Intent: The Emergence of Genetic Therapies for Sickle Cell Anemia

14 March 2024

Benz Jr, E. J., Silberstein, L. E., and Panepinto, J. (2024). “Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia. *Blood*, 143(11), 967-970. <https://doi.org/10.1182/blood.2023021598>

Clonal Selection of Hematopoietic Stem Cells after Gene Therapy for Sickle Cell Disease

16 November 2023

Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., et al. (2023). Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. *Nat Med*, 29(12), 3175-3183. <https://doi.org/10.1038/s41591-023-02636-6>

Molecular Basis and Genetic Modifiers of Thalassemia

10 March 2023

Tesio, N. and Bauer, D. E. (2023). Molecular basis and genetic modifiers of thalassemia. *Hematol Oncol Clin North Am*, 37(2), 273-299. <https://doi.org/10.1016/j.hoc.2022.12.001>

Base Editing of Human Hematopoietic Stem Cells

03 January 2023

Zeng, J., Casirati, G., Nguyen, M. A., et al. (2023). Base editing of human hematopoietic stem cells. In *Base Editors: Methods and Protocols* (pp. 43-62). New York, NY: Springer US. https://doi.org/10.1007/978-1-0716-2879-9_5

Development of a Double shmiR Lentivirus Effectively Targeting Both BCL11A and ZNF410 for Enhanced Induction of Fetal Hemoglobin to Treat β -Hemoglobinopathies

03 August 2022

Liu, B., Brendel, C., Vinjamur, D. S., et al. (2022). Development of a double shmiR lentivirus effectively targeting both BCL11A and ZNF410 for enhanced induction of fetal hemoglobin to treat β -hemoglobinopathies. *Mol Ther*, 30(8), 2693-2708. <https://doi.org/10.1016/j.ymthe.2022.05.002>

Optimization of Nuclear Localization Signal Composition Improves CRISPR-Cas12a Editing Rates in Human Primary Cells

14 June 2022

Luk, K., Liu, P., Zeng, J., et al. (2022). Optimization of nuclear localization signal composition improves CRISPR-Cas12a editing rates in human primary cells. *GEN Biotechnol*, 1(3), 271-284. <https://doi.org/10.1089/genbio.2022.0003>

Editing Outside the Body: Ex Vivo Gene-Modification for Beta-Hemoglobinopathy Cellular Therapy

03 November 2021

Rosanwo, T.O. and Bauer, D.E. (2021). Editing outside the body: Ex vivo gene-modification for beta-hemoglobinopathy cellular therapy. *Mol Ther*, 29(11), 3163-3178. <https://doi.org/10.1016/j.ymthe.2021.10.002>

Update on the Cure Sickle Cell Initiative

5 February 2021

Silberstein, L. E., and Telen, M. J. (2021). Update on the Cure Sickle Cell Initiative. *The Hematologist*, 18(2).

CRISPR/Cas9 Gene Editing for Curing Sickle Cell Disease

01 February 2021

Park, S.H. and Bao, G. (2021). CRISPR/Cas9 gene editing for curing sickle cell disease. *Transfus Apher Sci*, 60(1), 103060. <https://doi.org/10.1016/j.transci.2021.103060>

Magnetic Forces Enable Control of Biological Processes In Vivo

12 January 2021

Bao, G. (2021). Magnetic forces enable control of biological processes in vivo. *J Appl Mech*, 88(3), 030801. <https://doi.org/10.1115/1.4049331>

Accelerating the Science of SCD Therapies—Is a Cure Possible?

08 August 2019

Benz, E. J., Mondoro, T. H., and Gibbons, G. H. (2019). Accelerating the science of SCD therapies—Is a cure possible? *JAMA*, 322(10), 921. <https://doi.org/10.1001/jama.2019.11419>

HEMATOPOIETIC CELL TRANSPLANT (HCT)

Long-Term Quality of Life after Hematopoietic Cell Transplant for Sickle Cell Disease in Childhood: A STELLAR Interim Analysis

06 August 2024

Arnold, S. D., Bakshi, N., Ross, D., et al. (2024). Long term quality of life after hematopoietic cell transplant for sickle cell disease in childhood: A STELLAR interim analysis. *Am J Hematol*, 99(10), 2037–2040. <https://doi.org/10.1002/ajh.27436>

Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease

9 January 2023

Eapen, M., Brazaskas, R., Williams, D. A., et al. (2023). Secondary neoplasms after hematopoietic cell transplant for sickle cell disease. *J Clin Oncol*, 41(12), 2227–2237. <https://doi.org/10.1200/JCO.22.01203>

Sickle Cell Transplantation Evaluation of Long-term and Late Effects Registry (STELLAR) to Compare Long-term Outcomes After Hematopoietic Cell Transplantation to Those in Siblings Without Sickle Cell Disease and in Nontransplanted Individuals with Sickle Cell Disease: Design and Feasibility Study

06 July 2022

Krishnamurti, L., Arnold, S. D., Haight, A., et al. (2022). Sickle cell transplantation evaluation of long-term and late effects registry (STELLAR) to compare long-term outcomes after hematopoietic cell transplantation to those in siblings without sickle cell disease and in nontransplanted individuals with sickle cell disease: design and feasibility study. *JMIR Res Protoc*, 11(7), e36780. <https://doi.org/10.2196/36780>

Long-term Survival after Hematopoietic Cell Transplant for Sickle Cell Disease Compared to the United States Population

15 March 2022

St Martin, A., Hebert, K. M., Serret-Larmande, A., et al. (2022). Long-term survival after hematopoietic cell transplant for sickle cell disease compared to the United States population. *Transplant Cell Ther*, 28(6), 325.e1–325.e7. <https://doi.org/10.1016/j.jtct.2022.03.014>

A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study

28 October 2021

Veludhandi, A., Ross, D., Sinha, C. B., et al. (2021). A decision support tool for allogeneic hematopoietic stem cell transplantation for children with sickle cell disease: Acceptability and usability study. *JMIR Form Res*, 5(10), e30093. <https://doi.org/10.2196/30093>

Hematopoietic Cell Transplantation for Sickle Cell Disease

04 January 2021

Krishnamurti, L. (2021). Hematopoietic cell transplantation for sickle cell disease. *Front Pediatr*, 8, 551170. <https://doi.org/10.3389/fped.2020.551170>

MENTAL HEALTH

Assessing Psychosocial Risk and Resilience to Support Readiness for Gene Therapy in Sickle Cell Disease: A Consensus Statement

21 August 2024

Hardy, S. J., Crosby, L. E., Porter, J. S., et al. (2024). Assessing psychosocial risk and resilience to support readiness for gene therapy in sickle cell disease: A consensus statement. *JAMA Netw Open*, 7(8), e2429443–e2429443. <https://doi.org/10.1001/jamanetworkopen.2024.29443>

Mental Health Challenges Associated with Sickle Cell Disease and Strategies to Address Them: Reflections from a Community Input Panel

25 March 2026

Adeyokunnu, A., Avant, H., Hardy, S., et al. (2026). Mental health challenges associated with sickle cell disease and strategies to address them: Reflections from a community input panel. *J Natl Med Assoc*, 118(2), 178–182. <https://doi.org/10.1016/j.jnma.2025.12.002>

MICROFLUIDICS

Catch Bonds in Sickle Cell Disease: Shear-Enhanced Adhesion of Red Blood Cells to Laminin

20 June 2023

Goreke, U., Iram, S., Singh, G., et al. (2023). Catch bonds in sickle cell disease: shear-enhanced adhesion of red blood cells to laminin. *Biophys J*, 122(12), 2564–2576. <https://doi.org/10.1016/j.bpj.2023.05.010>

Membrane Bending and Sphingomyelinase-Associated, Sulfatide-Dependent Hypoxic Adhesion of Sickle Mature Erythrocytes

11 May 2023

Goreke, U., Kucukal, E., Wang, F., et al. (2023). Membrane bending and sphingomyelinase-associated, sulfatide-dependent hypoxic adhesion of sickle mature erythrocytes. *Blood Adv*, 7(10), 2094-2104. <https://doi.org/10.1182/bloodadvances.2022008392>

A Microfluidic Device for Assessment of E-Selectin-Mediated Neutrophil Recruitment to Inflamed Endothelium and Prediction of Therapeutic Response in Sickle Cell Disease

15 February 2023

Man, Y., Kucukal, E., Liu, S., et al. (2023). A microfluidic device for assessment of E-selectin-mediated neutrophil recruitment to inflamed endothelium and prediction of therapeutic response in sickle cell disease. *Biosens Bioelectron*, 222, 114921. <https://doi.org/10.1016/j.bios.2022.114921>

Emerging Functional Microfluidic Assays for the Study of Thromboinflammation in Sickle Cell Disease

01 November 2022

An, R., and Gurkan, U. A. (2022). Emerging functional microfluidic assays for the study of thromboinflammation in sickle cell disease. *Curr Opin Hematol*, 29(6), 327-334. <https://doi.org/10.1097/MOH.0000000000000731>

Antithrombin-III Mitigates Thrombin-Mediated Endothelial Cell Contraction and Sickle Red Blood Cell Adhesion in Microscale Flow

13 July 2022

Wulftange, W. J., Kucukal, E., Man, Y., et al. (2022). Antithrombin-III mitigates thrombin-mediated endothelial cell contraction and sickle red blood cell adhesion in microscale flow. *Br J Haematol*, 198(5), 893-902. <https://doi.org/10.1111/bjh.18328>

Size and Density Measurements of Single Sickle Red Blood Cells Using Microfluidic Magnetic Levitation

15 February 2022

Goreke, U., Bode, A., Yaman, S., et al. (2022). Size and density measurements of single sickle red blood cells using microfluidic magnetic levitation. *Lab Chip*, 22(4), 683-696. <https://doi.org/10.1039/d1lc00686j>

Integrating Deep Learning with Microfluidics for Biophysical Classification of Sickle Red Blood Cells Adhered to Laminin

29 November 2021

Praljak, N., Iram, S., Goreke, U., et al. (2021). Integrating deep learning with microfluidics for biophysical classification of sickle red blood cells adhered to laminin. *PLoS Comput Biol*, 17(11), e1008946. <https://doi.org/10.1371/journal.pcbi.1008946>

Microfluidic Assessment of Red Blood Cell Mediated Microvascular Occlusion

19 May 2021

Man, Y., Kucukal, E., An, R., et al. (2020). Microfluidic assessment of red blood cell mediated microvascular occlusion. *Lab Chip*, 20(12), 2086-2099. <https://doi.org/10.1039/d0lc00112k>

Biophysical and Rheological Biomarkers of Red Blood Cell Physiology and Pathophysiology

01 May 2021

Gurkan U. A. (2021). Biophysical and rheological biomarkers of red blood cell physiology and pathophysiology. *Curr Opin Hematol*, 28(3), 138-149. <https://doi.org/10.1097/MOH.0000000000000639>

Concurrent Assessment of Deformability and Adhesiveness of Sickle Red Blood Cells by Measuring Perfusion of an Adhesive Artificial Microvascular Network

28 April 2021

Lu, M., Kanne, C. K., Reddington, R. C., et al. (2021). Concurrent assessment of deformability and adhesiveness of sickle red blood cells by measuring perfusion of an adhesive artificial microvascular network. *Front Physiol*, 12. <https://doi.org/10.3389/fphys.2021.633080>

Microfluidic Electrical Impedance Assessment of Red Blood Cell-Mediated Microvascular Occlusion

05 March 2021

Man, Y., Maji, D., An, R., et al. (2021). Microfluidic electrical impedance assessment of red blood cell-mediated microvascular occlusion. *Lab Chip*, 21(6), 1036–1048. <https://doi.org/10.1039/d0lc01133a>

Standardized Microfluidic Assessment of Red Blood Cell-Mediated Microcapillary Occlusion: Association with Clinical Phenotype and Hydroxyurea Responsiveness in Sickle Cell Disease

09 January 2021

Man, Y., Kucukal, E., An, R., et al. (2021). Standardized microfluidic assessment of red blood cell-mediated microcapillary occlusion: Association with clinical phenotype and hydroxyurea responsiveness in sickle cell disease. *Microcirculation*, 28(2). <https://doi.org/10.1111/micc.12662>

Leukocyte Adhesion to P-Selectin and the Inhibitory Role of Crizanlizumab in Sickle Cell Disease: A Standardized Microfluidic Assessment

10 March 2020

Man, Y., Goreke, U., Kucukal, E., et al. (2020). Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment. *Blood Cells Mol Dis*, 83, 102424. <https://doi.org/10.1016/j.bcmed.2020.102424>

POST-GENE THERAPY, SAFETY

Synthetic Oligonucleotides Contain Synthesis Errors That Are Propagated into the Genome by Editing Through Homology-directed Repair

03 November 2025

Wyman, S., Romero Garcia, Z., Heo, S.J., et al. (2025). Synthetic oligonucleotides contain synthesis errors that are propagated into the genome by editing through homology-directed repair. *Blood*, 146(1): 4321. <https://doi.org/10.1182/blood-2025-4321>

Human Genetic Diversity Alters Off-Target Outcomes of Therapeutic Gene Editing

15 December 2022

Cancellieri, S., Zeng, J., Lin, L. Y., et al. (2023). Human genetic diversity alters off-target outcomes of therapeutic gene editing. *Nat Genet*, 55(1), 34-43. <https://doi.org/10.1038/s41588-022-01257-y>

Comprehensive Analysis and Accurate Quantification of Unintended Large Gene Modifications Induced by CRISPR-Cas9 Gene Editing

21 October 2022

Park, S. H., Cao, M., Pan, Y., et al. (2022). Comprehensive analysis and accurate quantification of unintended large gene modifications induced by CRISPR-Cas9 gene editing. *Sci Adv*, 8(42), eabo7676. <https://doi.org/10.1126/sciadv.abo7676>

Identification and Validation of CRISPR/Cas9 Off-Target Activity in Hematopoietic Stem and Progenitor Cells

05 May 2022

Park, S. H., Lee, C. M., and Bao, G. (2022). Identification and validation of CRISPR/Cas9 off-target activity in hematopoietic stem and progenitor cells. In *Stem Cell Assays: Methods and Protocols* (pp. 281-306). New York, NY: Springer US. https://doi.org/10.1007/978-1-0716-1979-7_19

Tools for Experimental and Computational Analyses of Off-Target Editing by Programmable Nucleases

07 December 2020

Bao, X. R., Pan, Y., Lee, C. M., et al. (2021). Tools for experimental and computational analyses of off-target editing by programmable nucleases. *Nat Protoc*, 16(1), 10–26. <https://doi.org/10.1038/s41596-020-00431-y>

REPRODUCTIVE HEALTH

Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation

05 July 2024

George, S. A., Veludhandi, A., Xiang, Y., et al. (2024). Reproductive health assessment and reports of fertility counseling in pediatric and adolescent patients with sickle cell disease after hematopoietic cell transplantation. *Transplant Cell Ther*, 30(9), 912-e1. <https://doi.org/10.1016/j.jtct.2024.06.029>

Female Reproductive Health Outcomes After Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?

09 May 2023

Meacham, L. R., George, S., Veludhandi, A., et al. (2023). Female reproductive health outcomes after hematopoietic cell transplantation for sickle cell disease: is reduced intensity better than myeloablative conditioning? *Transplant Cell Ther*, 29(8), 531-e1. <https://doi.org/10.1016/j.jtct.2023.05.004>

Parental Perspective on the Risk of Infertility and Fertility Preservation Options for Children and Adolescents with Sickle Cell Disease Considering Hematopoietic Stem Cell Transplantation

13 April 2023

Sinha, C. B., Meacham, L. R., Bakshi, N., et al. (2023). Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation. *Pediatr Blood Cancer*, 70(7), e30276. <https://doi.org/10.1002/pbc.30276>

SCD COMMUNITY OUTREACH

Process and Strategies for Patient Engagement and Outreach in the Sickle Cell Disease (SCD) Community to Promote Clinical Trial Participation

26 April 2022

Byrnes, C., Botello-Harbaum, M., Clemons, T., et al. (2022). Process and strategies for patient engagement and outreach in the sickle cell disease (SCD) community to promote clinical trial participation. *J Natl Med Assoc*, 114(2), 211-217. <https://doi.org/10.1016/j.jnma.2022.01.003>

Towards Access for All: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

08 September 2021

Adair, J. E., Androski, L., Bayigga, L., et al. (2023). Towards access for all: 1st working group report for the global gene therapy initiative (GGTI). *Gene Therapy*, 30(3), 216-221. <https://doi.org/10.1038/s41434-021-00284-4>

SCD PATHOPHYSIOLOGY

Missing the Mark(ers): Circulating Endothelial Cells and Endothelial-Derived Microvesicles are Elevated in Sickle Cell Disease

23 December 2024

Beckman, J.D., Zhang, P., Nguyen, J., et al. (2024) Missing the mark(ers): circulating endothelial cells and endothelial-derived extracellular vesicles are elevated in sickle cell disease plasma. *Front. Immunol.* 15, 1493904. <https://doi.org/10.3389/fimmu.2024.1493904>

Genetic Reversal of the Globin Switch Concurrently Modulates Both Fetal and Sickle Hemoglobin and Reduces Red Cell Sickling.

20 September 2023

De Souza, D. C., Hebert, N., Esrick, E. B., et al. (2023). Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling. *Nat Commun*, 14(1), 5850. <https://doi.org/10.1038/s41467-023-40923-5>

Sickle Red Blood Cell-Derived Extracellular Vesicles Activate Endothelial Cells and Enhance Sickle Red Cell Adhesion Mediated by Von Willebrand Factor.

05 January 2023

An, R., Man, Y., Cheng, K., et al. (2023). Sickle red blood cell-derived extracellular vesicles activate endothelial cells and enhance sickle red cell adhesion mediated by von Willebrand factor. *Br J Haematol*, 201(3), 552-563. <https://doi.org/10.1111/bjh.18616>

Red Blood Cell Adhesion to ICAM-1 is Mediated by Fibrinogen and is Associated with Right-to-Left Shunts in Sickle Cell Disease

10 August 2020

Kucukal, E., Man, Y., Quinn, E., et al. (2020). Red blood cell adhesion to ICAM-1 is mediated by fibrinogen and is associated with right-to-left shunts in sickle cell disease. *Blood Adv*, 4(15), 3688-3698. <https://doi.org/10.1182/bloodadvances.2020001656>

Whole Blood Viscosity and Red Blood Cell Adhesion: Potential Biomarkers for Targeted and Curative Therapies in Sickle Cell Disease

13 July 2020

Kucukal, E., Man, Y., Hill, A., et al. (2020). Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease. *Am J Hematol*, 95(11), 1246-1256. <https://doi.org/10.1002/ajh.25933>

Paper-Based Microchip Electrophoresis for Point-of-Care Hemoglobin Testing

07 April 2020

Hasan, M., Fraiwan, A., An, R., et al. (2020). Paper-based microchip electrophoresis for point-of-care hemoglobin testing. *Analyst*, 145(7), 2525-2542. <https://doi.org/10.1039/c9an02250c>
